Moors & Cabot’s AstraZeneca AZN Stock Holding History

Moors & Cabot’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-250	Closed	-$2K	–	904
2021 Q3	$2K	Buy	+250	New	+$29.1K	﹤0.01%	848

Other funds holding AZN

Evelyn Partners London $46.9B AUM

Investor AB Stockholm, Sweden $14.4B AUM 4.07% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Moors & Cabot's AZN Position: Q2 2026 in Review

Moors & Cabot reduced its AstraZeneca (AZN) stake by 0.73% in Q2 2026, selling an estimated $9.4K and leaving 6,836 shares worth $1.3M. The position accounts for 0.05% of the portfolio, ranked #325.

Moors & Cabot first reported a position in AZN in Q1 2014 and has held it in 50 quarters since. The position peaked at $1.36M in Q1 2026. 1,507 funds tracked by Wall St. Rank hold AZN as of Q2 2026.

Moors & Cabot held 6,836 shares of AstraZeneca worth $1.3M as of Q2 2026.
Moors & Cabot sold 50 AstraZeneca shares in Q2 2026, an estimated $9.4K.
AstraZeneca made up 0.05% of Moors & Cabot's portfolio in Q2 2026, its #325 holding.
Moors & Cabot first reported a position in AstraZeneca in Q1 2014 and has held it in 50 quarters since.
Moors & Cabot's AstraZeneca position peaked at $1.36M in Q1 2026.
1,507 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2026.

Based on Moors & Cabot's 13F filing for Q2 2026, filed 10 Aug 2026.